Atea Pharmaceuticals, Inc.

AVIR Healthcare Biotechnology

In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

4.32 0.21 −4.64%
Market cap
$363.3M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
n/a
Altman Z
9.33
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
7.80 7.67 7.59 16.32
Current Ratio
8.13 7.89 7.82 16.66
Net Debt/EBITDA
6.18 5.28 5.42 7.08
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.13 1.02 0.63 0.96
Capex/Depreciation
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.46) (0.59) (0.35) (0.51)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.46) (0.59) (0.35) (0.51)
Cash per Share
2.74 3.23 3.70 4.17
Shareholders Equity per Share
2.55 2.95 3.38 3.99
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.55 2.95 3.38 3.99
Free Cash Flow
(37.08) (46.39) (28.22) (40.37)
Working Capital
200.54 229.83 271.21 315.96
Net Current Asset Value
200.54 229.83 271.21 308.96
Other line items
Average Payables
9.45 8.42 8.70 4.65
Average Assets
311.94 353.52 389.94 416.96
Average Common Equity
284.29 322.40 357.15 387.15

Fold the line items

Columns are period end dates